A 6-Gene Signature For Outcome Prediction Of Grade Ii/Iii Glioma

2002 Background: Grade II and III gliomas are very heterogeneous in their outcome, leaving some uncertainty as to what the best treatment is for the individual patient. Methods: We used multiple datasets totaling 756 glioma patients to develop a prognostic 6-gene signature for grade II and III gliomas. Three risk groups were defined (low, medium, and high risk). This 6-gene classifier was then validated in multiple independent glioma data sets totaling over 500 patients and translated into a PCR-based assay. Results: The classifier was validated in a 214 grade II/III glioma patient independent validation set (TCGA, HR=4.03; 95% CI, 1.82-8.92; p= 0.001, for low vs high risk group) and a 287 patient grade IV glioblastoma set (updated TCGA, HR, 2.42; 95% CI, 1.69-3.47; pu003c 0.001, for low vs high risk group). The classifier was then translated into a PCR based assay in an independent 32 grade II/III glioma patient pilot cohort (multi-institutional, HR=6.3; 95% CI, 1.7-23.6; p= 0.006, for low vs high risk group...